These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22051602)

  • 1. An intravenous stimulus package for oncolytic virotherapy.
    Vile R; Melcher A
    Mol Ther; 2011 Nov; 19(11):1930-2. PubMed ID: 22051602
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapeutic potential of oncolytic vaccinia virus.
    Thorne SH
    Immunol Res; 2011 Aug; 50(2-3):286-93. PubMed ID: 21717084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in gene therapy using oncolytic vaccinia virus as vectors.
    Yang X; Huang B; Deng L; Hu Z
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2433-2440. PubMed ID: 30293118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.
    Myers R; Coviello C; Erbs P; Foloppe J; Rowe C; Kwan J; Crake C; Finn S; Jackson E; Balloul JM; Story C; Coussios C; Carlisle R
    Mol Ther; 2016 Sep; 24(9):1627-33. PubMed ID: 27375160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Giving oncolytic vaccinia virus more BiTE.
    Albelda SM; Thorne SH
    Mol Ther; 2014 Jan; 22(1):6-8. PubMed ID: 24384909
    [No Abstract]   [Full Text] [Related]  

  • 9. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy.
    Huang LL; Li X; Liu K; Zou B; Xie HY
    Anal Bioanal Chem; 2019 Feb; 411(4):925-933. PubMed ID: 30523361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
    Kirn DH; Thorne SH
    Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy: combining first-rate science with an unmet clinical need.
    Seymour LW
    Hum Gene Ther; 2011 Apr; 22(4):387-8. PubMed ID: 21486159
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.
    Adelfinger M; Gentschev I; Grimm de Guibert J; Weibel S; Langbein-Laugwitz J; Härtl B; Murua Escobar H; Nolte I; Chen NG; Aguilar RJ; Yu YA; Zhang Q; Frentzen A; Szalay AA
    PLoS One; 2014; 9(8):e104337. PubMed ID: 25093734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.
    Downs-Canner S; Guo ZS; Ravindranathan R; Breitbach CJ; O'Malley ME; Jones HL; Moon A; McCart JA; Shuai Y; Zeh HJ; Bartlett DL
    Mol Ther; 2016 Aug; 24(8):1492-501. PubMed ID: 27203445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.